Results 1 to 10 of about 115,286 (266)

Phase 1, First‐In‐Human, Single‐/Multiple‐Ascending Dose Study of Iluzanebart in Healthy Volunteers [PDF]

open access: yesAnnals of Clinical and Translational Neurology
Objective To evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of iluzanebart, a fully human monoclonal antibody TREM2 (triggering receptor expressed on myeloid cells 2) agonist, after single‐ (SAD) and multiple‐ascending‐dose ...
Andreas Meier   +8 more
doaj   +2 more sources

DNA analysis and validation for species identification of seized helmeted hornbill (Rhinoplax vigil) casques

open access: goldForensic Science International: Animals and Environments, 2023
Helmeted hornbills (Rhinoplax vigil, J.R. Forster, 1781) are ‘Critically Endangered’ due to illegal hunting for their casques which are carved and traded for ornamental purposes.
Chloe E.R. Hatten   +6 more
doaj   +2 more sources

Case Report: Marked Survival Advantage of Two Colorectal Cancer Patients with Liver Metastases Treated with Vigil and FOLFOX-6

open access: yesVaccines, 2021
Colorectal cancer is the third most diagnosed cancer in the United States. Five-year survival rates remain low and many patients will develop liver metastasis.
Vedin Barve   +2 more
exaly   +3 more sources

Pilot Study of Combination Gemogenovatucel-T (Vigil) and Durvalumab in Women With Relapsed BRCA-wt Triple-Negative Breast or Ovarian Cancer

open access: yesClinical Medicine Insights: Oncology, 2022
Background: Gemogenovatucel-T (Vigil) is a triple-function autologous tumor cell immunotherapy which expresses granulocyte-macrophage colony-stimulating factor and decreases expression of furin and downstream TGF-β1 and TGF-β2.
John J Nemunaitis
exaly   +2 more sources

Vigil

open access: yesApparatus. Film, Media and Digital Cultures of Central and Eastern Europe, 2020
Tibor Hajas's video and article.
Tibor Hajas
doaj   +2 more sources

Exome sequencing shows same pattern of clonal tumor mutational burden, intratumor heterogenicity and clonal neoantigen between autologous tumor and Vigil product [PDF]

open access: yesScientific Reports
Retrospective data support overall survival (OS) advantage to high clonal tumor mutation burden (cTMB), high clonal neoantigen load (cNEO) and low intratumor heterogeneity (ITH) in cancer patients who receive immunotherapy.
David Willoughby   +10 more
doaj   +2 more sources

3D engineered scaffold for large-scale Vigil immunotherapy production [PDF]

open access: yesScientific Reports
Previously, we reported successful cellular expansion of a murine colorectal carcinoma cell line (CT-26) using a three-dimensional (3D) engineered extracellular matrix (EECM) fibrillar scaffold structure.
Fabienne Kerneis   +13 more
doaj   +2 more sources

Long-Term Follow-Up of Gemogenovatucel-T (Vigil) Survival and Molecular Signals of Immune Response in Recurrent Ovarian Cancer

open access: yesVaccines, 2021
Aim: To determine the relationship between gene expression profile (GEP) and overall survival (OS) by NanoString following treatment with Vigil. Patients and Methods: Recurrent ovarian cancer patients (n = 21) enrolled in prior clinical trials.
Rodney P Rocconi   +2 more
exaly   +3 more sources

Recuperación colectiva de la Biblioteca Popular Constancio C. Vigil

open access: diamondA&P Continuidad, 2019
El presente artículo tiene como objetivo narrar la experiencia del Proyecto de extensión “Recuperación Colectiva de la Biblioteca Vigil”. El mismo resultó del trabajo en conjunto entre la currícula de grado del Taller de Proyecto Arquitectónico, el ...
Susana Paganini
doaj   +2 more sources

Home - About - Disclaimer - Privacy